Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia

Acta Oncol. 2014 Jan;53(1):158-60. doi: 10.3109/0284186X.2013.802838. Epub 2013 Jun 11.

Authors

Naohiro Watanabe¹, Yoshio Nakahara, Hiroyuki Taniguchi, Tomoki Kimura, Yasuhiro Kondoh, Kensuke Kataoka, Koji Sakamoto

Affiliation

¹ Department of Respiratory Medicine and Allergy, Tosei General Hospital , Seto, Aichi , Japan.

PMID: 23750540
DOI: 10.3109/0284186X.2013.802838

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Aged
Carcinoma, Non-Small-Cell Lung / complications
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Chronic Disease
Crizotinib
Fatal Outcome
Humans
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / pathology
Lung Diseases, Interstitial / therapy
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Male
Oncogene Proteins, Fusion / genetics
Oncogene Proteins, Fusion / metabolism*
Protein Kinase Inhibitors / adverse effects*
Pyrazoles / adverse effects*
Pyridines / adverse effects*

Substances

EML4-ALK fusion protein, human
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib